AIM ImmunoTech Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards

by Barry101 | Dec 17, 2024 | Press Release

A Plan for Compliance has been UndertakenOCALA, Fla., Dec. 17, 2024 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), announced today that it received a notice (the “Notice”) from the NYSE American LLC (the...

AIM ImmunoTech Announces Election of Three Incumbent Board Members at Annual Meeting

by Barry101 | Dec 17, 2024 | Press Release

OCALA, Fla. – AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that, based on the preliminary vote count of its proxy solicitor, shareholders have elected three of the Company’s incumbent directors...

AIM ImmunoTech Reminds Shareholders to Vote “FOR” All Four Incumbent Board Members on the WHITE Universal Proxy Card

by Barry101 | Dec 16, 2024 | Press Release

Urges Shareholders to Ensure Their Voices Are Heard and to Protect Their Investment by Supporting Current Board Believes Incumbent Board is Best Positioned to Continue Overseeing the Clinical Development of Ampligen and Deliver Long-Term Value for All Shareholders...

AIM ImmunoTech Urges Shareholders to Vote on the WHITE Universal Proxy Card “FOR” All Four Incumbent Board Members

by Barry101 | Dec 12, 2024 | Press Release

Believes Annual Meeting Outcome is Critical to Future of the Company and that the Current Board is Best Positioned to Continue Clinical Trial Momentum, Commercialize Ampligen and Deliver Long-Term Value for Shareholders In AIM’s View, the Activist Group’s...

AIM ImmunoTech Expands Patent Portfolio with New Netherlands Composition and Methods Patent Covering Ampligen for Use in the Post-COVID Condition of Fatigue

by Barry101 | Dec 12, 2024 | Press Release

OCALA, Fla., Dec. 12, 2024 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the Netherlands Patent Office (Octrooicentrum Nederland) has granted Patent No. 2,032,813 – a compositions and...